Table of Contents Author Guidelines Submit a Manuscript
Multiple Sclerosis International
Volume 2011, Article ID 767083, 18 pages
http://dx.doi.org/10.1155/2011/767083
Review Article

Cerebrospinal Fluid and Blood Biomarkers of Neuroaxonal Damage in Multiple Sclerosis

Neurology Clinic, Clinical Center of Serbia, Dr Subotica 6, P.O. Box 12, 11129 Belgrade 102, Serbia

Received 20 December 2010; Accepted 8 February 2011

Academic Editor: Robert Weissert

Copyright © 2011 Irena Dujmovic. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Barkhof, P. A. Calabresi, D. H. Miller, and S. C. Reingold, “Imaging outcomes for neuroprotection and repair in multiple sclerosis trials,” Nature Reviews Neurology, vol. 5, no. 5, pp. 256–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. M. Frohman, M. Filippi, O. Stuve et al., “Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions,” Archives of Neurology, vol. 62, no. 9, pp. 1345–1356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Charcot, Lecons sur les maladies du systeme nerveux faites a la Salpetriere, A. Delahaye, Paris, France, 1880.
  4. N. A. Losseff, S. L. Webb, J. I. O'Riordan et al., “Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression,” Brain, vol. 119, no. 3, pp. 701–708, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. N. A. Losseff, L. Wang, H. M. Lai et al., “Progressive cerebral atrophy in multiple sclerosis. A serial MRI study,” Brain, vol. 119, no. 6, pp. 2009–2019, 1996. View at Google Scholar · View at Scopus
  6. B. D. Trapp, J. Peterson, R. M. Ransohoff, R. Rudick, S. Mörk, and L. Bö, “Axonal transection in the lesions of multiple sclerosis,” New England Journal of Medicine, vol. 338, no. 5, pp. 278–285, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. B. D. Trapp, R. Ransohoff, and R. Rudick, “Axonal pathology in multiple sclerosis: relationship to neurologic disability,” Current Opinion in Neurology, vol. 12, no. 3, pp. 295–302, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Bjartmar, G. Kidd, S. Mörk, R. Rudick, and B. D. Trapp, “Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients,” Annals of Neurology, vol. 48, no. 6, pp. 893–901, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. B. D. Trapp and K. A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Ferguson, M. K. Matyszak, M. M. Esiri, and V. H. Perry, “Axonal damage in acute multiple sclerosis lesions,” Brain, vol. 120, no. 3, pp. 393–399, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. Peterson, L. Bö, S. Mörk, A. Chang, and B. D. Trapp, “Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions,” Annals of Neurology, vol. 50, no. 3, pp. 389–400, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Huizinga, W. Gerritsen, N. Heijmans, and S. Amor, “Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments,” Neurobiology of Disease, vol. 32, no. 3, pp. 461–470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Vercellino, S. Masera, M. Lorenzatti et al., “Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter,” Journal of Neuropathology and Experimental Neurology, vol. 68, no. 5, pp. 489–502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. H. Miller, A. J. Thompson, and M. Filippi, “Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis,” Journal of Neurology, vol. 250, no. 12, pp. 1407–1419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Ceccarelli, M. A. Rocca, A. Falini et al., “Normal-appearing white and grey matter damage in MS: a volumetric and diffusion tensor MRI study at 3.0 Tesla,” Journal of Neurology, vol. 254, no. 4, pp. 513–518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Aboul-Enein, M. Krššák, R. Höftberger, D. Prayer, and W. Kristoferitsch, “Reduced NAA-Levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla,” PLoS ONE, vol. 5, no. 7, article e11625, 2010. View at Publisher · View at Google Scholar
  17. C. Bjartmar and B. D. Trapp, “Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences,” Current Opinion in Neurology, vol. 14, no. 3, pp. 271–278, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Bjartmar, J. R. Wujek, and B. D. Trapp, “Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease,” Journal of the Neurological Sciences, vol. 206, no. 2, pp. 165–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Dutta and B. D. Trapp, “Pathogenesis of axonal and neuronal damage in multiple sclerosis,” Neurology, vol. 68, no. 22, supplement, pp. S22–S31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Giovannoni, A. J. E. Green, and E. J. Thompson, “Are there any body fluid markers of brain atrophy in multiple sclerosis?” Multiple Sclerosis, vol. 4, no. 3, pp. 138–142, 1998. View at Google Scholar · View at Scopus
  21. C. E. Teunissen, P. C. Dijkstra, and C. Polman, “Biological markers in CSF and blood for axonal degeneration in multiple sclerosis,” Lancet Neurology, vol. 4, no. 1, pp. 32–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Bielekova and R. Martin, “Development of biomarkers in multiple sclerosis,” Brain, vol. 127, no. 7, pp. 1463–1478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Kuhle, A. Regeniter, D. Leppert et al., “A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein,” Journal of Neuroimmunology, vol. 220, no. 1-2, pp. 114–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Van der Walt, H. Butzkueven, S. Kolbe et al., “Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade,” Pharmacology and Therapeutics, vol. 126, no. 1, pp. 82–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Brettschneider, A. Petzold, A. Junker, and H. Tumani, “Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 2, pp. 143–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Lutterotti, T. Berger, and M. Reindl, “Biological markers for multiple sclerosis,” Current Medicinal Chemistry, vol. 14, no. 18, pp. 1956–1965, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Comabella, M. Fernández, R. Martin et al., “Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis,” Brain, vol. 133, no. 4, pp. 1082–1093, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. L. Jones and A. J. Coles, “Campath-1H treatment of multiple sclerosis,” Neurodegenerative Diseases, vol. 5, no. 1, pp. 27–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Wiendl and R. Hohlfeld, “Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes,” Neurology, vol. 72, no. 11, pp. 1008–1015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Leray, J. Yaouanq, E. Le Page et al., “Evidence for a two-stage disability progression in multiple sclerosis,” Brain, vol. 133, no. 7, pp. 1900–1913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Daumer, A. Neuhaus, S. Morrissey, R. Hintzen, and G. C. Ebers, “MRI as an outcome in multiple sclerosis clinical trials,” Neurology, vol. 72, no. 8, pp. 705–711, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Bø, C. A. Vedeler, H. Nyland, B. D. Trapp, and S. J. Mørk, “Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration,” Multiple Sclerosis, vol. 9, no. 4, pp. 323–331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Frischer, S. Bramow, A. Dal-Bianco et al., “The relation between inflammation and neurodegeneration in multiple sclerosis brains,” Brain, vol. 132, no. 5, pp. 1175–1189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Lassmann, “What drives disease in multiple sclerosis: inflammation or neurodegeneration?” Clinical and Experimental Neuroimmunology, vol. 1, pp. 2–11, 2010. View at Google Scholar
  35. E. Silber and M. K. Sharief, “Axonal degeneration in the pathogenesis of multiple sclerosis,” Journal of the Neurological Sciences, vol. 170, no. 1, pp. 11–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Derfuss, K. Parikh, S. Velhin et al., “Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 20, pp. 8302–8307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Derfuss, C. Linington, R. Hohlfeld, and E. Meinl, “Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury,” Journal of Molecular Medicine, vol. 88, no. 8, pp. 753–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Neumann, I. M. Medana, J. Bauer, and H. Lassmann, “Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases,” Trends in Neurosciences, vol. 25, no. 6, pp. 313–319, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. L. H. Kasper and J. Shoemaker, “Multiple sclerosis immunology: the healthy immune system vs the MS immune system,” Neurology, vol. 74, pp. S2–S8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Kierdorf, Y. Wang, and H. Neumann, “Immune-mediated CNS damage,” Results and Problems in Cell Differentiation, vol. 51, pp. 173–196, 2010. View at Publisher · View at Google Scholar
  41. D. O. Willenborg, M. A. Staykova, and W. B. Cowden, “Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review,” Journal of Neuroimmunology, vol. 100, no. 1-2, pp. 21–35, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. G. C. Brown and V. Borutaite, “Nitric oxide inhibition of mitochondrial respiration and its role in cell death,” Free Radical Biology and Medicine, vol. 33, no. 11, pp. 1440–1450, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. R. E. Gonsette, “Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity,” Journal of the Neurological Sciences, vol. 274, no. 1-2, pp. 48–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Werner, D. Pitt, and C. S. Raine, “Glutamate excitotoxicity—a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis?” Journal of Neural Transmission, no. 60, pp. 375–385, 2000. View at Google Scholar · View at Scopus
  45. G. Lazzarino, A. M. Amorini, M. J. Eikelenboom et al., “Cerebrospinal fluid ATP metabolites in multiple sclerosis,” Multiple Sclerosis, vol. 16, no. 5, pp. 549–554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Mahad, H. Lassmann, and D. Turnbull, “Review: mitochondria and disease progression in multiple sclerosis,” Neuropathology and Applied Neurobiology, vol. 34, no. 6, pp. 577–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Owens, “The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage,” Current Opinion in Neurology, vol. 16, no. 3, pp. 259–265, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. S. G. Waxman, M. J. Craner, and J. A. Black, “Na+ channel expression along axons in multiple sclerosis and its models,” Trends in Pharmacological Sciences, vol. 25, no. 11, pp. 584–591, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. M. N. Rasband, J. Tayler, Y. Kaga et al., “CNP is required for maintenance of axon-glia interactions at nodes of ranvier in the CNS,” GLIA, vol. 50, no. 1, pp. 86–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. O. W. Howell, J. L. Rundle, A. Garg, M. Komada, P. J. Brophy, and R. Reynolds, “Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis,” Journal of Neuropathology and Experimental Neurology, vol. 69, no. 10, pp. 1017–1033, 2010. View at Publisher · View at Google Scholar
  51. S. Petratos, M. F. Azari, E. Ozturk, R. Papadopoulos, and C. C. A. Bernard, “Novel therapeutic targets for axonal degeneration in multiple sclerosis,” Journal of Neuropathology and Experimental Neurology, vol. 69, no. 4, pp. 323–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Yang, Y. Liu, P. Wei et al., “Silencing Nogo—a promotes functional recovery in demyelinating disease,” Annals of Neurology, vol. 67, no. 4, pp. 498–507, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Spitzer, H. W. Klafki, K. Blennow et al., “CNEUPRO: novel biomarkers for neurodegenerative diseases,” International Journal of Alzheimer's Disease, vol. 2010, Article ID 548145, 12 pages, 2010. View at Publisher · View at Google Scholar
  54. C. E. Teunissen, E. Iacobaeus, M. Khademi et al., “Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis,” Neurology, vol. 72, no. 15, pp. 1322–1329, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. M. K. Lee and D. W. Cleveland, “Neuronal intermediate filaments,” Annual Review of Neuroscience, vol. 19, pp. 187–217, 1996. View at Google Scholar · View at Scopus
  56. M. M. Gresle, G. Shaw, B. Jarrott et al., “Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis,” Journal of Neuroscience Research, vol. 86, no. 16, pp. 3548–3555, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Petzold, “Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss,” Journal of the Neurological Sciences, vol. 233, no. 1-2, pp. 183–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. M. E. Goldstein, N. H. Sternberger, and L. A. Sternberger, “Phosphorylation protects neurofilaments against proteolysis,” Journal of Neuroimmunology, vol. 14, no. 2, pp. 149–160, 1987. View at Google Scholar · View at Scopus
  59. J. P. Julien and W. E. Mushynski, “Neurofilaments in health and disease,” Progress in Nucleic Acid Research and Molecular Biology, vol. 61, pp. 1–23, 1998. View at Google Scholar · View at Scopus
  60. E. Fuchs and D. W. Cleveland, “A structural scaffolding of intermediate filaments in health and disease,” Science, vol. 279, no. 5350, pp. 514–519, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. J. N. Lycke, J. E. Karlsson, O. Andersen, and L. E. Rosengren, “Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 3, pp. 402–404, 1998. View at Google Scholar · View at Scopus
  62. A. Petzold, M. J. Eikelenboom, G. Keir et al., “Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 2, pp. 206–211, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. K. Semra, O. A. Seidi, and M. K. Sharief, “Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability,” Journal of Neuroimmunology, vol. 122, no. 1-2, pp. 132–139, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Malmeström, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke, “Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS,” Neurology, vol. 61, no. 12, pp. 1720–1725, 2003. View at Google Scholar · View at Scopus
  65. N. Norgren, P. Sundström, A. Svenningsson, L. Rosengren, T. Stigbrand, and M. Gunnarsson, “Neurofilament and glial fibrillary acidic protein in multiple sclerosis,” Neurology, vol. 63, no. 9, pp. 1586–1590, 2004. View at Google Scholar · View at Scopus
  66. M. J. Eikelenboom, A. Petzold, R. H. C. Lazeron et al., “Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy,” Neurology, vol. 60, no. 2, pp. 219–223, 2003. View at Google Scholar · View at Scopus
  67. S. Haghighi, O. Andersen, A. Odén, and L. Rosengren, “Cerebrospinal fluid markers in MS patients and their healthy siblings,” Acta Neurologica Scandinavica, vol. 109, no. 2, pp. 97–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. L. E. Rosengren, J. E. Karlsson, J. O. Karlsson, L. I. Persson, and C. Wikkelsø, “Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF,” Journal of Neurochemistry, vol. 67, no. 5, pp. 2013–2018, 1996. View at Google Scholar · View at Scopus
  69. E. T. Lim, D. Grant, M. Pashenkov et al., “Cerebrospinal fluid levels of brain specific proteins in optic neuritis,” Multiple Sclerosis, vol. 10, no. 3, pp. 261–265, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. I. Miyazawa, I. Nakashima, A. Petzold, K. Fujihara, S. Sato, and Y. Itoyama, “High CSF neurofilament heavy chain levels in neuromyelitis optica,” Neurology, vol. 68, no. 11, pp. 865–867, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Petzold, K. Rejdak, and G. T. Plant, “Axonal degenaration and inflammation in acute optic neuritis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 8, pp. 1178–1180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni, “Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 1, pp. 59–66, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. N. Norgren, L. Rosengren, and T. Stigbrand, “Elevated neurofilament levels in neurological diseases,” Brain Research, vol. 987, no. 1, pp. 25–31, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Silber, Y. K. Semra, N. A. Gregson, and M. K. Sharief, “Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit,” Neurology, vol. 58, no. 9, pp. 1372–1381, 2002. View at Google Scholar · View at Scopus
  75. J. Salzer, A. Svenningsson, and P. Sundström, “Neurofilament light as a prognostic marker in multiple sclerosis,” Multiple Sclerosis, vol. 16, no. 3, pp. 287–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Petzold, M. J. Eikelenboom, G. Keir et al., “The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers,” Multiple Sclerosis, vol. 12, no. 3, pp. 325–328, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Petzold, D. Brassat, P. Mas et al., “Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 3, pp. 281–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. E. T. Lim, F. Sellebjerg, C. V. Jensen et al., “Acute axonal damage predicts clinical outcome in patients with multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 5, pp. 532–536, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Bartoš, L. Fialová, J. Soukupová, J. Kukal, I. Malbohan, and J. Piťha, “Antibodies against light neurofilaments in multiple sclerosis patients,” Acta Neurologica Scandinavica, vol. 116, no. 2, pp. 100–107, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Ehling, A. Lutterotti, J. Wanschitz et al., “Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 6, pp. 601–606, 2004. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Fialová, A. Bartoš, J. Soukupová, J. Švarcová, P. Ridzoň, and I. Malbohan, “Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases,” Folia Biologica, vol. 55, no. 1, pp. 23–26, 2009. View at Google Scholar · View at Scopus
  82. A. Bartoš, L. Fialová, J. Soukupová, J. Kukal, I. Malbohan, and J. Pit'ha, “Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis,” Journal of Neurology, vol. 254, no. 1, pp. 20–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Švarcová, L. Fialová, A. Bartoš, M. Šteinbachová, and I. Malbohan, “Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis,” European Journal of Neurology, vol. 15, no. 11, pp. 1173–1179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Forooghian, R. K. Cheung, W. C. Smith, P. O'Connor, and H. M. Dosch, “Enolase and arrestin are novel nonmyelin autoantigens in multiple sclerosis,” Journal of Clinical Immunology, vol. 27, no. 4, pp. 388–396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. D. B. Braxton, M. Williams, D. Kamali, S. Chin, R. Liem, and N. Latov, “Specificity of human anti-neurofilament autoantibodies,” Journal of Neuroimmunology, vol. 21, no. 2-3, pp. 193–203, 1989. View at Google Scholar · View at Scopus
  86. B. O. Fabriek, J. N. P. Zwemmer, C. E. Teunissen et al., “In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 190–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Prat and J. Antel, “Pathogenesis of multiple sclerosis,” Current Opinion in Neurology, vol. 18, no. 3, pp. 225–230, 2005. View at Google Scholar · View at Scopus
  88. K. Kamath, E. Oroudjev, and M. A. Jordan, “Determination of microtubule dynamic instability in living cells,” Methods in Cell Biology, vol. 97, pp. 1–14, 2010. View at Publisher · View at Google Scholar
  89. K. H. Downing, “Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics,” Annual Review of Cell and Developmental Biology, vol. 16, pp. 89–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. N. B. Laferrière, T. H. MacRae, and D. L. Brown, “Tubulin synthesis and assembly in differentiating neurons,” Biochemistry and Cell Biology, vol. 75, no. 2, pp. 103–117, 1997. View at Google Scholar · View at Scopus
  91. D. Girard and J. L. Senécal, “Anti-microfilament IgG antibodies in normal adults and in patients with autoimmune diseases: immunofluorescence and immunoblotting analysis of 201 subjects reveals polyreactivity with microfilament-associated proteins,” Clinical Immunology and Immunopathology, vol. 74, no. 2, pp. 193–201, 1995. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Kulakowska, W. Drozdowski, A. Sadzynski, R. Bucki, and P. A. Janmey, “Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders,” European Journal of Neurology, vol. 15, no. 6, pp. 584–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Paunio, H. Kangash, O. Heinonen et al., “Cells of the neuronal lineage play a major role in the generation of amyloid precursor fragments in gelsolin-related amyloidosis,” Journal of Biological Chemistry, vol. 273, no. 26, pp. 16319–16324, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. H. L. Yin, D. J. Kwiatokowski, J. E. Mole, and F. S. Cole, “Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin,” Journal of Biological Chemistry, vol. 259, no. 8, pp. 5271–5276, 1984. View at Google Scholar · View at Scopus
  95. W. M. Lee and R. M. Galbraith, “The extracellular actin-scavenger system and actin toxicity,” New England Journal of Medicine, vol. 326, no. 20, pp. 1335–1341, 1992. View at Google Scholar · View at Scopus
  96. A. Kułakowska, N. J. Ciccarelli, Q. Wen et al., “Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis,” BMC Neurology, vol. 10, article 107, 2010. View at Publisher · View at Google Scholar
  97. C. Ballatore, V. M. Y. Lee, and J. Q. Trojanowski, “Tau-mediated neurodegeneration in Alzheimer's disease and related disorders,” Nature Reviews Neuroscience, vol. 8, no. 9, pp. 663–672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. G. V. W. Johnson and W. H. Stoothoff, “Tau phosphorylation in neuronal cell function and dysfunction,” Journal of Cell Science, vol. 117, no. 24, pp. 5721–5729, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Bandyopadhyay, G. Li, H. Yin, and J. Kuret, “Tau aggregation and toxicity in a cell culture model of tauopathy,” Journal of Biological Chemistry, vol. 282, no. 22, pp. 16454–16464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. J. M. Anderson, R. Patani, R. Reynolds et al., “Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis,” Acta Neuropathologica, vol. 117, no. 5, pp. 583–589, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. J. M. Anderson, D. W. Hampton, R. Patani et al., “Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis,” Brain, vol. 131, no. 7, pp. 1736–1748, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. J. M. Anderson, R. Patani, R. Reynolds et al., “Abnormal tau phosphorylation in primary progressive multiple sclerosis,” Acta Neuropathologica, vol. 119, no. 5, pp. 591–600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Brettschneider, M. Maier, S. Arda et al., “Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 3, pp. 261–265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. J. Guimarães, M. J. Cardoso, and M. J. Sá, “Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 3, pp. 354–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. K. Hein Née Maier, A. Köhler, R. Diem et al., “Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis,” Neuroscience Letters, vol. 436, no. 1, pp. 72–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Vališ, R. Taláb, P. Šťourač, C. Andrýs, and J. Masopust, “Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients,” Neuroendocrinology Letters, vol. 29, no. 6, pp. 971–976, 2008. View at Google Scholar
  107. E. Kapaki, G. P. Paraskevas, M. Michalopoulou, and K. Kilidireas, “Increased cerebrospinal fluid tau protein in multiple sclerosis,” European Neurology, vol. 43, no. 4, pp. 228–232, 2000. View at Google Scholar · View at Scopus
  108. H. Bartosik-Psujek and J. J. Archelos, “Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG,” Journal of Neurology, vol. 251, no. 4, pp. 414–420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. H. Bartosik-Psujek and Z. Stelmasiak, “The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis,” Journal of Neural Transmission, vol. 113, no. 3, pp. 339–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Terzi, A. Birinci, E. Çetinkaya, and M. K. Onar, “Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis,” Acta Neurologica Scandinavica, vol. 115, no. 5, pp. 325–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. F. J. Jiménez-Jiménez, J. M. Zurdo, A. Hernanz et al., “Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis,” Acta Neurologica Scandinavica, vol. 106, no. 6, pp. 351–354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  112. K. Rostasy, E. Withut, D. Pohl et al., “Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis,” Journal of Child Neurology, vol. 20, no. 10, pp. 822–825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Martínez-Yélamos, A. Saiz, J. Bas, J. J. Hernandez, F. Graus, and T. Arbizu, “Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis,” Neuroscience Letters, vol. 363, no. 1, pp. 14–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. S. D. Süssmuth, H. Reiber, and H. Tumani, “Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases,” Neuroscience Letters, vol. 300, no. 2, pp. 95–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Gajofatto, S. Monaco, M. Fiorini et al., “Assessment of outcome predictors in first-episode acute myelitis a retrospective study of 53 cases,” Archives of Neurology, vol. 67, no. 6, pp. 724–730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Schneider, G. W. Araújo, K. Trajkovic et al., “Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis,” Journal of Biological Chemistry, vol. 279, no. 53, pp. 55833–55839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Scheurich, P. P. Urban, N. Koch-Khoury, and A. Fellgiebel, “CSF phospho-tau is independent of age, cognitive status and gender of neurological patients,” Journal of Neurology, vol. 257, no. 4, pp. 609–614, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. P. R. Turner, K. O'Connor, W. P. Tate, and W. C. Abraham, “Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory,” Progress in Neurobiology, vol. 70, no. 1, pp. 1–32, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. E. H. Koo, S. S. Sisodia, D. R. Archer et al., “Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 4, pp. 1561–1565, 1990. View at Google Scholar · View at Scopus
  120. W. Brück and C. Stadelmann, “Inflammation and degeneration in multiple sclerosis,” Neurological Sciences, vol. 24, no. 5, pp. S265–S267, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Gehrmann, R. B. Banati, M. L. Cuzner, G. W. Kreutzberg, and J. Newcombe, “Amyloid precursor protein (APP) expression in multiple sclerosis lesions,” Glia, vol. 15, no. 2, pp. 141–151, 1995. View at Google Scholar · View at Scopus
  122. N. Mattsson, M. Axelsson, S. Haghighi et al., “Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis,” Multiple Sclerosis, vol. 15, no. 4, pp. 448–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. U. Andreasson, E. Portelius, M. E. Andersson, K. Blennow, and H. Zetterberg, “Aspects of beta-amyloid as a biomarker for Alzheimer's disease,” Biomarkers in Medicine, vol. 1, no. 1, pp. 59–78, 2007. View at Google Scholar
  124. J. Kim, V. M. Miller, Y. Levites et al., “BRI2 (ITM2b) inhibits Aβ deposition in vivo,” Journal of Neuroscience, vol. 28, no. 23, pp. 6030–6036, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. V. K. Harris, A. Diamanduros, P. Good, E. Zakin, V. Chalivendra, and S. A. Sadiq, “Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis,” Neurobiology of Disease, vol. 40, no. 1, pp. 331–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. F. Mori, S. Rossi, G. Sancesario et al., “Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis,” Neuropsychopharmacology, vol. 36, no. 3, pp. 559–568, 2011. View at Publisher · View at Google Scholar
  127. T. Tokuda, T. Oide, A. Tamaoka, K. Ishii, S. Matsuno, and S. Ikeda, “Prednisolone (30–60 mg/day) for diseases other than AD decreases amyloid β-peptides in CSF,” Neurology, vol. 58, no. 9, pp. 1415–1418, 2002. View at Google Scholar
  128. C. Bjartmar, J. Battistuta, N. Terada, E. Dupree, and B. D. Trapp, “N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve,” Annals of Neurology, vol. 51, no. 1, pp. 51–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. J. R. Moffett, B. Ross, P. Arun, C. N. Madhavarao, and A. M. A. Namboodiri, “N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology,” Progress in Neurobiology, vol. 81, no. 2, pp. 89–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. D. J. Rigotti, M. Inglese, and O. Gonen, “Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders,” American Journal of Neuroradiology, vol. 28, no. 10, pp. 1843–1849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. O. Khan, Y. Shen, C. Caon et al., “Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multilple sclerosis,” Multiple Sclerosis, vol. 11, no. 6, pp. 646–651, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Tiberio, D. T. Chard, D. R. Altmann et al., “Metabolite changes in early relapsing-remitting multiple sclerosis: a two year follow-up study,” Journal of Neurology, vol. 253, no. 2, pp. 224–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. D. J. Rigotti, O. Gonen, R. I. Grossman et al., “Global N-acetylaspartate declines even in benign multiple sclerosis,” American Journal of Neuroradiology, vol. 32, no. 1, pp. 204–209, 2011. View at Publisher · View at Google Scholar
  134. M. Van Au Duong, B. Audoin, Y. Le Fur et al., “Relationships between gray matter metabolic abnormalities and white matter inflammation in patients at the very early stage of MS: a MRSI study,” Journal of Neurology, vol. 254, no. 7, pp. 914–923, 2007. View at Publisher · View at Google Scholar
  135. K. Viala, J. L. Stievenart, E. A. Cabanis, O. Lyon-Caen, and A. Tourbah, “Study with localized proton magnetic resonance spectroscopy of 31 multiple sclerosis lesions: correlations with clinical and MRI features,” Revue Neurologique, vol. 157, no. 1, pp. 35–44, 2001. View at Google Scholar
  136. N. De Stefano, P. M. Matthews, L. Fu et al., “Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study,” Brain, vol. 121, no. 8, pp. 1469–1477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  137. N. De Stefano, S. Narayanan, G. S. Francis et al., “Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability,” Archives of Neurology, vol. 58, no. 1, pp. 65–70, 2001. View at Google Scholar · View at Scopus
  138. N. De Stefano, G. Iannucci, M. P. Sormani et al., “MR correlates of cerebral atrophy in patients with multiple sclerosis,” Journal of Neurology, vol. 249, no. 8, pp. 1072–1077, 2002. View at Publisher · View at Google Scholar · View at Scopus
  139. S. Narayanan, N. De Stefano, G. S. Francis et al., “Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b,” Journal of Neurology, vol. 248, no. 11, pp. 979–986, 2001. View at Publisher · View at Google Scholar
  140. M. Colucci, L. Roccatagliata, E. Capello et al., “The 14-3-3 protein in multiple sclerosis: a marker of disease severity,” Multiple Sclerosis, vol. 10, no. 5, pp. 477–481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. B. Jasperse, C. Jakobs, M. J. Eikelenboom et al., “N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry,” Journal of Neurology, vol. 254, no. 5, pp. 631–637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. R. T. Cunningham, J. I. Morrow, C. F. Johnston, and K. D. Buchanan, “Serum neurone-specific enolase concentrations in patients with neurological disorders,” Clinica Chimica Acta, vol. 230, no. 2, pp. 117–124, 1994. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Koch, J. Mostert, D. Heersema, A. Teelken, and J. De Keyser, “Plasma S100β and NSE levels and progression in multiple sclerosis,” Journal of the Neurological Sciences, vol. 252, no. 2, pp. 154–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. P. J. H. Jongen, K. J. B. Lamers, W. H. Doesburg, W. A. J. G. Lemmens, and O. R. Hommes, “Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis,” Journal of Neurology Neurosurgery and Psychiatry, vol. 63, no. 4, pp. 446–451, 1997. View at Google Scholar
  145. V. I. Zannis, “Genetic polymorphism in human apolipoprotein E,” Methods in Enzymology, vol. 128, pp. 823–851, 1986. View at Google Scholar · View at Scopus
  146. H. L. Zhang, J. Wu, and J. Zhu, “The immune-modulatory role of apolipoprotein e with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis,” Clinical and Developmental Immunology, vol. 2010, Article ID 186813, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. M. Mulder, A. Blokland, D. J. Van Den Berg et al., “Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging,” Laboratory Investigation, vol. 81, no. 7, pp. 953–960, 2001. View at Google Scholar · View at Scopus
  148. B. B. Gelman, N. Rifai, R. H. Christenson, and L. M. Silverman, “Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis,” Annals of Clinical and Laboratory Science, vol. 18, no. 1, pp. 46–52, 1988. View at Google Scholar · View at Scopus
  149. J. Carlsson, V. W. Armstrong, H. Reiber, K. Felgenhauer, and D. Seidel, “Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid,” Clinica Chimica Acta, vol. 196, no. 2-3, pp. 167–176, 1991. View at Publisher · View at Google Scholar · View at Scopus
  150. P. Hogh, A. Oturai, K. Schreiber et al., “Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate,” Multiple Sclerosis, vol. 6, no. 4, pp. 226–230, 2000. View at Google Scholar · View at Scopus
  151. N. De Stefano, M. L. Bartolozzi, B. Nacmias et al., “Influence of apolipoprotein E ε4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis,” Archives of Neurology, vol. 61, no. 4, pp. 536–540, 2004. View at Publisher · View at Google Scholar
  152. E. Portaccio, V. Zipoli, B. Goretti et al., “ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis,” Acta Neurologica Scandinavica, vol. 120, no. 6, pp. 439–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  153. F. Fazekas, S. Strasser-Fuchs, H. Kollegger et al., “Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis,” Neurology, vol. 57, no. 5, pp. 853–857, 2001. View at Google Scholar · View at Scopus
  154. M. Pinholt, J. L. Frederiksen, P. S. Andersen, and M. Christiansen, “Apo E in multiple sclerosis and optic neuritis: the Apo E-ε4 allele is associated with progression of multiple sclerosis,” Multiple Sclerosis, vol. 11, no. 5, pp. 511–515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  155. C. Enzinger, S. Ropele, S. Strasser-Fuchs et al., “Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E ε4 allele,” Archives of Neurology, vol. 60, no. 1, pp. 65–70, 2003. View at Google Scholar
  156. A. Sena, R. Couderc, V. Ferret-Sena et al., “Apolipoprotein e polymorphism interacts with cigarette smoking in progression of multiple sclerosis,” European Journal of Neurology, vol. 16, no. 7, pp. 832–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. J. Shi, C. B. Zhao, T. L. Vollmer, T. M. Tyry, and S. M. Kuniyoshi, “APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosis,” Neurology, vol. 70, no. 3, pp. 185–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. E. Portaccio, B. Goretti, V. Zipoli et al., “APOE-ε4 is not associated with cognitive impairment in relapsing—remitting multiple sclerosis,” Multiple Sclerosis, vol. 15, no. 12, pp. 1489–1494, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. O. Gaillard, A. Gervais, D. Meillet et al., “Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation,” Journal of the Neurological Sciences, vol. 158, no. 2, pp. 180–186, 1998. View at Publisher · View at Google Scholar · View at Scopus
  160. N. Rifai, R. H. Christenson, B. B. Gelman, and L. M. Silverman, “Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination,” Clinical Chemistry, vol. 33, no. 7, pp. 1155–1157, 1987. View at Google Scholar · View at Scopus
  161. D. Chiasserini, M. Di Filippo, A. Candeliere et al., “CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis,” European Journal of Neurology, vol. 15, no. 9, pp. 998–1001, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. G. Giovannoni, “Multiple sclerosis cerebrospinal fluid biomarkers,” Disease Markers, vol. 22, no. 4, pp. 187–196, 2006. View at Google Scholar · View at Scopus
  163. V. Hoffmann, W. Kuhn, S. Schimrigk et al., “Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients,” European Journal of Neurology, vol. 13, no. 1, pp. 72–76, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. B. G. M. Van Engelen, K. J. B. Lamers, F. J. M. Gabreels, R. A. Wevers, W. J. A. Van Geel, and G. F. Borm, “Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid,” Clinical Chemistry, vol. 38, no. 6, pp. 813–816, 1992. View at Google Scholar · View at Scopus
  165. J. Finsterer, M. Exner, and H. Rumpold, “Cerebrospinal fluid neuron-specific enolase in non-selected patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 64, no. 6, pp. 553–558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  166. A. B. Oestreicher, P. N. E. De Graan, W. H. Gispen, J. Verhaagen, and L. H. Schrama, “B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system,” Progress in Neurobiology, vol. 53, no. 6, pp. 627–686, 1997. View at Publisher · View at Google Scholar · View at Scopus
  167. C. E. Teunissen, C. D. Dijkstra, B. Jasperse et al., “Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis,” Neuropathology and Applied Neurobiology, vol. 32, no. 3, pp. 318–331, 2006. View at Publisher · View at Google Scholar · View at Scopus
  168. V. Leoni, “Oxysterols as markers of neurological disease—a review,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 69, no. 1, pp. 22–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  169. V. D. Karrenbauer, V. Leoni, EE. T. Lim et al., “Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis,” Clinical Neurology and Neurosurgery, vol. 108, no. 5, pp. 456–460, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. L. Bretillon, Å. Sidén, L. O. Wahlund et al., “Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases,” Neuroscience Letters, vol. 293, no. 2, pp. 87–90, 2000. View at Publisher · View at Google Scholar · View at Scopus
  171. V. Leoni, T. Masterman, U. Diczfalusy, G. De Luca, J. Hillert, and I. Björkhem, “Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis,” Neuroscience Letters, vol. 331, no. 3, pp. 163–166, 2002. View at Publisher · View at Google Scholar
  172. C. E. Teunissen, C. D. Dijkstra, C. H. Polman, E. L. J. Hoogervorst, K. Von Bergmann, and D. Lütjohann, “Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients,” Neuroscience Letters, vol. 347, no. 3, pp. 159–162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  173. V. Leoni, T. Masterman, F. S. Mousavi et al., “Diagnostic use of cerebral and extracerebral oxysterols,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 2, pp. 186–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  174. J. De Seze, K. Peoc'h, D. Ferriby, T. Stojkovic, J. L. Laplanche, and P. Vermersch, “14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis,” Journal of Neurology, vol. 249, no. 5, pp. 626–627, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. A. Martínez-Yélamos, A. Saiz, R. Sanchez-Valle et al., “14-3-3 Protein in the CSF as prognostic marker in early multiple sclerosis,” Neurology, vol. 57, no. 4, pp. 722–724, 2001. View at Google Scholar · View at Scopus
  176. A. Martínez-Yélamos, A. Rovira, R. Sánchez-Valle et al., “CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS,” Journal of Neurology, vol. 251, no. 10, pp. 1278–1279, 2004. View at Publisher · View at Google Scholar · View at Scopus
  177. L. Bretillon, D. Lütjohann, L. Ståhle et al., “Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface,” Journal of Lipid Research, vol. 41, no. 5, pp. 840–845, 2000. View at Google Scholar
  178. I. Björkhem, S. Meaney, and A. M. Fogelman, “Brain cholesterol: long secret life behind a barrier,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 806–815, 2004. View at Publisher · View at Google Scholar · View at Scopus
  179. V. Leoni, T. Masterman, P. Patel, S. Meaney, U. Diczfalusy, and I. Björkhem, “Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers,” Journal of Lipid Research, vol. 44, no. 4, pp. 793–799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  180. P. F. Boston, P. Jackson, and R. J. Thompson, “Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders,” Journal of Neurochemistry, vol. 38, no. 5, pp. 1475–1482, 1982. View at Google Scholar · View at Scopus
  181. J. I. Satoh, K. Kurohara, M. Yukitake, and Y. Kuroda, “The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture,” European Neurology, vol. 41, no. 4, pp. 216–225, 1999. View at Publisher · View at Google Scholar · View at Scopus
  182. J.-I. Satoh, T. Yamamura, and K. Arima, “The 14-3-3 protein ε isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes,” American Journal of Pathology, vol. 165, no. 2, pp. 577–592, 2004. View at Google Scholar
  183. H. Slaets, D. Dumont, J. Vanderlocht et al., “Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3,” Proteomics, vol. 8, no. 6, pp. 1237–1247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  184. J. M. Woodcock, Y. Ma, C. Coolen et al., “Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function,” Cellular Signalling, vol. 22, no. 9, pp. 1291–1299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  185. F. Deisenhammer, R. Egg, G. Giovannoni et al., “EFNS guidelines on disease-specific CSF investigations,” European Journal of Neurology, vol. 16, no. 6, pp. 760–770, 2009. View at Publisher · View at Google Scholar · View at Scopus
  186. A. Saiz, F. Graus, J. Dalmau, A. Pifarré, C. Marín, and E. Tolosa, “Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders,” Annals of Neurology, vol. 46, no. 5, pp. 774–777, 1999. View at Publisher · View at Google Scholar · View at Scopus
  187. J. I. Satoh, M. Yukitake, K. Kurohara, H. Takashima, and Y. Kuroda, “Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis,” Journal of the Neurological Sciences, vol. 212, no. 1-2, pp. 11–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  188. D. N. Irani and D. A. Kerr, “14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis,” Lancet, vol. 355, no. 9207, p. 901, 2000. View at Google Scholar · View at Scopus
  189. B. N. Hammack, K. Y. C. Fung, S. W. Hunsucker et al., “Proteomic analysis of multiple sclerosis cerebrospinal fluid,” Multiple Sclerosis, vol. 10, no. 3, pp. 245–260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. D. Dumont, J. P. Noben, J. Raus, P. Stinissen, and J. Robben, “Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients,” Proteomics, vol. 4, no. 7, pp. 2117–2124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  191. A. J. Elderfield, J. Newcombe, C. Bolton, and R. J. Flower, “Lipocortins (annexins) 1, 2, 4 and 5 are increased in the central nervous system in multiple sclerosis,” Journal of Neuroimmunology, vol. 39, no. 1-2, pp. 91–100, 1992. View at Publisher · View at Google Scholar · View at Scopus
  192. M. J. Craner, A. C. Lo, J. A. Black et al., “Annexin II/PII is up-regulated in Purkinje cells in EAE and MS,” NeuroReport, vol. 14, no. 4, pp. 555–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  193. J. P. Noben, D. Dumont, N. Kwasnikowska et al., “Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry,” Journal of Proteome Research, vol. 5, no. 7, pp. 1647–1657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. S. Elkabes and H. Li, “Proteomic strategies in multiple sclerosis and its animal models,” Proteomics, vol. 1, no. 11, pp. 1393–1405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  195. N. Mattsson, U. Rüetschi, V. N. Podust et al., “Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis,” Journal of Neurochemistry, vol. 103, no. 5, pp. 1932–1939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  196. E. K. Mathey, T. Derfuss, M. K. Storch et al., “Neurofascin as a novel target for autoantibody-mediated axonal injury,” Journal of Experimental Medicine, vol. 204, no. 10, pp. 2363–2372, 2007. View at Publisher · View at Google Scholar · View at Scopus
  197. R. A. Linker, P. Brechlin, S. Jesse et al., “Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage,” PLoS ONE, vol. 4, no. 10, article e7624, 2009. View at Publisher · View at Google Scholar · View at Scopus
  198. H. Tumani, C. Teunissen, S. Süssmuth, M. Otto, A. C. Ludolph, and J. Brettschneider, “Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases,” Expert Review of Molecular Diagnostics, vol. 8, no. 4, pp. 479–494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  199. H. Tumani, H.-P. Hartung, B. Hemmer et al., “Cerebrospinal fluid biomarkers in multiple sclerosis,” Neurobiology of Disease, vol. 35, no. 2, pp. 117–127, 2009. View at Publisher · View at Google Scholar
  200. A. Petzold, A. Altintas, L. Andreoni et al., “Neurofilament ELISA validation,” Journal of Immunological Methods, vol. 352, no. 1-2, pp. 23–31, 2010. View at Publisher · View at Google Scholar
  201. C. E. Teunissen, A. Petzold, J. L. Bennett et al., “A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking,” Neurology, vol. 73, no. 22, pp. 1914–1922, 2009. View at Publisher · View at Google Scholar · View at Scopus